
Sun Pharma Switzerland Ltd. Wollerau

ANNUAL REPORT

01.04.2021 - 31.03.2022



Experfina AG, Picassoplatz 8, CH-4052 Basel

DETAILED BALANCE SHEET as at 31. March 2022

	Foreign currency		31.03.2022 CHF	31.03.2021 CHF	+/- CHF
ASSETS					
UBS AG, CC CHF			17,582.03	17,842.43	-260.40
UBS AG, CC USD	USD	27.61	25.75	0.00	25.75
UBS AG, CC EUR	EUR	11,649.58	12,136.75	35,076.10	-22,939.35
Cash at bank			29,744.53	52,918.53	-23,174.00
Debtors EUR	EUR	26,860.83	27,892.46	24,429.35	3,463.11
Debtor VAT			391.00	6,478.45	-6,087.45
Debtors			28,283.46	30,907.80	-2,624.34
Prepaid expenses			43,651.30	47,586.85	-3,935.55
Accrued revenues			43,651.30	47,586.85	-3,935.55
TOTAL CURRENT ASSETS			101,679.29	131,413.18	-29,733.89
TOTAL ASSETS			101,679.29	131,413.18	-29,733.89

DETAILED BALANCE SHEET as at 31. March 2022

	Foreign currency	31.03.2022 CHF	31.03.2021 CHF	+/- CHF
LIABILITIES				
Creditor pension fund		100.70	0.00	100.70
Creditors		100.70	0.00	100.70
Accrued liabilities		22,940.00	20,041.00	2,899.00
Accrued liabilities		22,940.00	20,041.00	2,899.00
TOTAL CURRENT LIABILITIES		23,040.70	20,041.00	2,999.70

DETAILED BALANCE SHEET as at 31. March 2022

	Foreign currency	31.03.2022 CHF	31.03.2021 CHF	+/- CHF
Share capital		100,000.00	100,000.00	0.00
Share Capital		100,000.00	100,000.00	0.00
Legal reserves		2,100.00	2,100.00	0.00
Legale reserve		2,100.00	2,100.00	0.00
Profit brought forward		9,272.18	17,173.31	-7,901.13
Loss of the period		-32,733.59	-7,901.13	-24,832.46
Loss		-23,461.41	9,272.18	-32,733.59
TOTAL SHAREHOLDER'S EQUITY		78,638.59	111,372.18	-32,733.59
TOTAL LIABILITIES		101,679.29	131,413.18	-29,733.89

DETAILED PROFIT AND LOSS ACCOUNT from 1. April 2021 till 31. March 2022

	2021 - 2022 CHF	2020 - 2021 CHF	+/- CHF
Revenues intra group	627,283.81	574,842.97	52,440.84
Income for Services	627,283.81	574,842.97	52,440.84
Total Operating income	627,283.81	574,842.97	52,440.84
Phone, Internet, IT	-2,664.49	-4,246.34	1,581.85
Management fees	-21,281.25	-16,000.00	-5,281.25
Administration fees	-5,675.00	-5,695.59	20.59
Audit	-3,675.00	-3,575.00	-100.00
Registration fees	-272,081.62	-223,131.39	-48,950.23
Public liability insurance	-309.85	-336.05	26.20
Other fees and charges	-356.45	-638.50	282.05
Legal fees	-10,028.36	0.00	-10,028.36
Administrative expenses	-316,072.02	-253,622.87	-62,449.15
Operating Result 1	311,211.79	321,220.10	-10,008.31

DETAILED PROFIT AND LOSS ACCOUNT from 1. April 2021 till 31. March 2022

	2021 - 2022 CHF	2020 - 2021 CHF	+/- CHF
Gross salary	-266,664.00	-263,072.20	-3,591.80
Refund of accident and daily sickness allowance	324.80	0.00	324.80
AHV/ALV	-20,244.55	-20,701.15	456.60
Pension fund	-28,414.15	-24,326.35	-4,087.80
Accident insurance	-2,157.15	-2,168.90	11.75
Disability insurance	-2,849.80	-2,814.85	-34.95
Travel fees effective	-4,197.85	-3,573.25	-624.60
Personal costs	-324,202.70	-316,656.70	-7,546.00
Bank charges	-368.41	-503.68	135.27
Exchange differences	-19,137.52	-11,714.10	-7,423.42
Financial expenses	-19,505.93	-12,217.78	-7,288.15
Financial result	-19,505.93	-12,217.78	-7,288.15
Operating result 2	-32,496.84	-7,654.38	-24,842.46
Taxes	-236.75	-246.75	10.00
Taxes	-236.75	-246.75	10.00
Loss of the period	-32,733.59	-7,901.13	-24,832.46

Sun Pharma Switzerland Ltd., Wollerau

Notes to the annual report as of 31. March 2022

1. Principles

1.1 General aspects

These financial statements were prepared according to the provisions of the Swiss Law on Accounting and Financial Reporting (32nd title of the Swiss code of Obligations). Where not prescribed by law, the significant accounting and valuation principles applied are described below. It should be noted that to ensure the company's going concern, the company's financial statements may be influenced by the creation and release of hidden reserves.

2. Information on balance sheet and income statement items

none

3. Other Informations

3.1 Full-time equivalents

The full-time equivalents were below 10.

3.2 Extraordinary expenses

In the profit and loss account is no extraordinary position in the current financial year.

3.3 Significant occurrence after the balance sheet date

There are no significant occurrence after the balance sheet date, which could impact the book value of the assets or liabilities or which should be disclosed here.

Sun Pharma Switzerland Ltd., Wollerau

Notes to the annual report as of 31. March 2022

4. Proposed Appropriation of retained earnings for the financial year 2021/2022

	2021/2022	2020/2021
	Betrag	Betrag
Retained earnings brought forward	9,272.00	17,173.00
Net loss of the year	-32,733.00	-7,901.00
Retained earnings available for appropriation	-23,461.00	9,272.00

The board of directors propose the following:

Allocation to legal reserves	0.00	0.00
To be carried forward	-23,461.00	9,272.00
TOTAL	-23,461.00	9,272.00